More Australians are overdosing on GHB

Healthed

writer

Healthed

Healthed

Jack Freestone, UNSW Sydney and Krista J. Siefried, UNSW Sydney

Gamma hydroxybutyrate – better known as GHB – is an increasingly popular illegal drug being used recreationally in Australia.

While it can create feelings of euphoria, disinhibition and increased libido, GHB carries serious risks. The difference between a recreational dose and an overdose of GHB – usually taken as a liquid – can be less than 0.5ml.

What is GHB?

GHB (also sometimes called “G”, “juice”, “Gina” or “fantasy”) has gained attention globally due to associated harms. It is generally a colourless and odourless liquid which may taste bitter or salty.

When taken at higher doses, GHB acts as a depressant, slowing down breathing and heart rate.

At low doses (about 1ml), it can cause effects such as euphoria, increased libido and lowered inhibitions. For this reason, GHB is often used as a party drug (for example, in night clubs) and to facilitate sex.

Other chemicals called gamma butyrolactone (GBL) and 1,4-butanediol (1,4-BD) are often sold or used as substitutes to GHB, producing broadly similar effects.

How widely is it used?

Only 0.2% of Australian residents report having used GHB in the past year. This is low compared to other drugs such as cannabis (11.5%) or cocaine (4.5%).

However, among certain groups GHB use is much higher.

In 2024, 12% of people who regularly take ecstasy and other illicit stimulants (such as methamphetamine) said they’d also used GHB in the previous six months. Among those who regularly inject drugs, it was 15%. This data is collected annually and shows GHB use has increased among these groups over the past five years.

Surveys of gay and bisexual men also indicate higher use: nearly 20% say they have taken GHB at least once in their life.

Risks of a ‘G-drop’ or ‘blow-out’

GHB carries a high risk for overdose. This is because there is a very small difference in a dose that produces euphoric or relaxing effects and one that causes a loss of consciousness.

A GHB overdose is often called a “G-drop” or “blow-out”. People who overdose may experience unconsciousness and muscle twitching, seizures and respiratory depression – when a person stops breathing.

Unfortunately, unlike overdoses caused by opioids – which may be reversed by administering naloxone – there is no drug that can reverse the effects of GHB.

Witnessing a GHB overdose can be very distressing. You should call emergency services on 000 and meanwhile keep the person’s airways clear and monitor their breathing.

Dependence and other harms

Harms related to GHB have been escalating over the past ten years. Notably, GHB-related ambulance attendances, emergency presentations and hospitalisations have increased. For example, in Victoria, ambulance attendances related to GHB increased 147% between 2012 and 2019.

People who use GHB at least once a day can become dependent. If someone is using GHB daily, it is always recommended they consult a medical provider before stopping. Suddenly stopping can cause severe and even life-threatening withdrawal symptoms.

Sex and consent

Because GHB decreases inhibitions and enhances libido, some people also choose to combine it with sex.

In our research, we’ve found those who do this often use a range of strategies to care for themselves and their partners. For example, they may communicate about their sexual interests, boundaries and limits beforehand, and communicate consent both verbally and non-verbally.

Several high-profile cases overseas and in Australia have also drawn attention to the use of GHB in drink spiking and drug-facilitated sexual assault.

These instances are deeply concerning. However, many studies show other drugs – such as cannabis and even alcohol – are more commonly used in drug-facilitated sexual assault.

Detecting GHB in cases of sexual assault can be difficult and the true prevalence of drug-facilitated sexual assault in Australia is unknown, meaning we don’t have consistent data on how often GHB is used in sexual assault.

If people who voluntarily use GHB for sex experience distressing sexual situations, research shows they may resist labelling these as sexual violence. This can mean, despite their anguish, they may not seek support from sexual assault services.

Our research suggests people who use GHB may be more willing to seek help when services use different language to offer support – focusing on “confusion” or “concern” about sexual encounters, rather than sexual violence.

Strategies to reduce harm

Our research also shows knowledge about GHB and harm reduction can make a difference. We interviewed 31 people who’d used GHB three or more times in the previous year.

They reported a range of strategies to keep themselves, their friends and sexual partners safe when using GHB. These include:

  • measuring every dose carefully
  • always starting with a low dose
  • spacing out doses over time
  • avoiding mixing GHB with other central nervous system depressants, such as alcohol
  • communicating openly about consent, sexual interests and boundaries when combining GHB with sex.

Shifting patterns

We still don’t know exactly why there is an increase in GHB use in Australia.

Possible factors include its low price and increased availability.

New groups using GHB, including people who inject drugs and women, may also contribute to the increase in harms such as hospitalisations. They may be less familiar with safer ways to use the drug. We need more research to understand why and how these new groups are using it.

There is also a lot we still need to learn about GHB’s long-term impacts on health and wellbeing.

Australian guidelines have been published on the management of GHB withdrawal.

However, there are few guidelines for clinicians and service providers about how best to work alongside people seeking to reduce their GHB use. We need more research to understand the experiences of people who use services aiming to reduce their use of GHB or withdraw.

Advice about drug use and treatment is available for free at the National Alcohol and Other Drug Hotline.

You can report unexpected overdoses to the Poisons Information Centre from anywhere in Australia on 131 126. In an emergency, call 000.

The National Sexual Assault, Family and Domestic Violence Counselling Line – 1800 RESPECT (1800 737 732) – is available 24 hours a day, seven days a week for any Australian who has experienced, or is at risk of, family and domestic violence and/or sexual assault.The Conversation

Jack Freestone, Postdoctoral Research Fellow, National Centre for Clinical Research on Emerging Drugs, UNSW Sydney and Krista J. Siefried, Senior Lecturer, National Centre for Clinical Research on Emerging Drugs, UNSW Sydney

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Prof Brendon Yee

Prof Brendon Yee

Obstructive Sleep Apnoea & Driving: The GP's Role

Dr Terri Foran

Dr Terri Foran

Non-Hormonal & Hormonal Options for Hot Flushes

Dr Adam Nelson

Dr Adam Nelson

Why is LDL Control Important?

Dr Anita Munoz

Dr Anita Munoz

Muscle Health in Chronic Disease: A Practical Guide for GPs

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Share this

Share this

Healthed

writer

Healthed

Test your knowledge

Recent articles

Latest GP poll

"I am concerned about disrupted continuity of care for patients that use 1800Medicare"

Strongly agree

0%

Slightly agree

0%

slightly disagree

0%

strongly disagree

0%

Recent podcasts

Listen to expert interviews.
Click to open in a new tab

Find your area of interest

Once you confirm you’ve read this article you can complete a Patient Case Review to earn 0.5 hours CPD in the Reviewing Performance (RP) category.

Select ‘Confirm & learn‘ when you have read this article in its entirety and you will be taken to begin your Patient Case Review.

Menopause and MHT

Multiple sclerosis vs antibody disease

Using SGLT2 to reduce cardiovascular death in T2D

Peripheral arterial disease